Dr. William R. Freeman, MD

Dr. Freeman practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Freeman's NPI, 1518983352, was assigned on July 14, 2006. Dr. Freeman graduated from Icahn School Of Medicine At Mount Sinai in 1979. Dr. Freeman holds California license G51579.

Dr. Freeman's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Freeman's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Freeman is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Freeman practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Freeman's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Freeman is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Freeman's licenses on file in 2 states: California and New York.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eyelid inflammation, glaucoma, hereditary corneal conditions and inflammation of iris among the conditions Dr. Freeman treats.

CMS data shows 20,813 Medicare services from Dr. Freeman across 14 procedure codes in 2024, for 570 Medicare patients. Medicare paid $1,205,494 for them.

CMS counts 570 Medicare patients who saw Dr. Freeman in 2024. The largest group is 75 to 84, with 220 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Freeman's median patient age at 71, with 54% women.

In 2024, Dr. Freeman wrote 138 Medicare Part D claims for 53 patients. 87% of them were for generic drugs. CMS names the drug for 93 of them, across 4 drugs with 11 or more claims each, at $2,279 in total drug cost. In 2023, CMS named 67 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Freeman for performance year 2024, reported as part of a group. Dr. Freeman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 25 procedures of cataract surgery by Dr. Freeman, more than 49% of the clinicians it reports for that procedure.

Dmand AI links 449 papers to Dr. Freeman, published from 2005 to 2025. 2023 was the busiest year, with 13. The most frequent topics are Visual Acuity, Retina and Fluorescein Angiography. Dr. Freeman has published most often in Retina. Dr. Freeman's most frequent co-authors are Jay Kumar Chhablani, MD, Michael Henry Goldbaum, MD and Iryna Anatoliyevna Falkenstein, MD.

CMS Open Payments shows 57 general payments to Dr. Freeman from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Allergan Inc. paid the most, $20,016. It also lists 3 research payments totaling $11,782 from 2020 to 2024.

Dmand AI lists 5 awards for Dr. Freeman, most recently America's Top Doctors in 2014.

Dr. Freeman graduated from Icahn School Of Medicine At Mount Sinai in 1979. Dr. Freeman is a member of AAO.

Dr. Freeman is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.